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U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
CENTERS FOR DISEASE CONTROL AND PREVENTION 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Division of Tuberculosis Elimination 
ADVISORY COUNCIL FOR THE ELIMINATION OF TUBERCULOSIS 
December 2-3, 2014 
Atlanta, Georgia 
Minutes of the Meeting 
The U.S. Department of Health and Human Services (HHS) and the Centers for Disease 
Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB 
Prevention (NCHHSTP), Division of Tuberculosis Elimination (DTBE) convened a meeting of the 
Advisory Council for the Elimination of Tuberculosis (ACET).  The proceedings were held on 
December 2-3, 2014 in Building 8 of CDC’s Corporate Square Campus, Conference Room 
A/B/C, in Atlanta, Georgia. 
ACET is chartered to provide advice to the Secretary of HHS and the Director of CDC regarding 
the elimination of tuberculosis (TB); make recommendations regarding policies, strategies, 
objectives and priorities; address the development and application of new technologies; provide 
guidance on CDC’s TB Prevention Research portfolio and program priorities; and review the 
extent to which progress has been made toward eliminating TB.  
Opening Session: December 2, 2014 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer (DFO) 
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Dr. Dean conducted a roll call to determine the ACET voting members, ex-officio members and 
liaison representatives who were attending the meeting either in person or remotely.  She 
announced that ACET meetings are open to the public and all comments made during the 
proceedings are a matter of public record. 
Dr. Dean reminded the ACET voting members of their responsibility to disclose any potential 
individual and/or institutional conflicts of interest for the public record and recuse themselves 
from voting or participating in these matters. 
 
CONFLICT OF INTEREST DISCLOSURES 
 
ACET Voting Member 
(Institution/Organization) Potential Conflict of Interest 
Ana Alvarez, MD, FAAP 
(University of Florida College of Medicine) No conflicts disclosed 
Lisa Armitige, MD, PhD 
(Heartland National Tuberculosis Center) No conflicts disclosed 
Jennifer Cochran, MPH 
(Massachusetts Department of Public Health) No conflicts disclosed 
Barbara Cole, RN, MSN, PHN 
(Riverside County Department of Public 
Health) 
No conflicts disclosed 
Susan Dorman, MD 
(Johns Hopkinds University School of 
Medicine) 
No conflicts disclosed 
Robert Horsburgh, Jr., MD, MUS 
(Boston University School of Public Health) 
No conflicts disclosed 
Eric Houpt, MD 
(University of Virginia) No conflicts disclosed 
Michael Lauzardo, MD, MSc 
(University of Florida College of Medicine) 
Recipient of federal funding from CDC for the 
Southeastern National Tuberculosis Center, a 
Regional Training and Medical Consultation Center 
(RTMCC) 
James Sunstrum, MD 
(Wayne County, Michigan TB Clinic) No conflicts disclosed 
David Warshauer, PhD 
(Wisconsin State Laboratory of Hygiene) No conflicts disclosed 
 
Dr. Dean announced that the voting members and ex-officio members in attendance constituted 
a quorum for ACET to conduct its business on December 2, 2014.  She called the proceedings 
to order at 8:38 a.m. and welcomed the participants to day 1 of the ACET meeting.  Dr. Dean 
noted the temporary and permanent changes to ACET’s membership. 
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• Biographical sketches of five new ACET members were included in the meeting packets: 
o Lisa Armitige, MD, PhD; Medical Consultant, Heartland National TB Center 
o Eric Houpt, MD; Professor, Division of Infectious Diseases and International Health, 
University of Virginia 
o Michael Lauzardo, MD, MSc; Chief, Division of Infectious Disease and Global 
Medicine, University of Florida College of Medicine 
o James Sunstrum, MD; TB Consultant, Wayne County TB Clinic 
o David Warshauer, PhD; Deputy Director, Communicable Disease, Wisconsin State 
Laboratory of Hygiene 
• Dr. Shama Ahuja has replaced Dr. David Trump as the liaison representative for the 
Council of State and Territorial Epidemiologists. 
• Dr. Michael Bartholomew would serve as the ex-officio member for the Indian Health 
Service in the absence of Dr. Susan Karol. 
• Ms. Marla Clifton would serve as the ex-officio member for the Department of Veterans 
Affairs in the absence of Dr. Gary Roselle. 
• CDR Edward Chin has replaced Ms. Tiffany Moore as the ex-officio member for the 
United States Marshals Service. 
• Mr. Kenyon Farrow would serve as the liaison representative for the Treatment Action 
Group in the absence of Ms. Colleen Daniels. 
• Dr. Amee Patrawalla has replaced Dr. Lee Reichman as the liaison representative for 
the American College of Chest Physicians. 
• Dr. Chana Rabiner has replaced Dr. Warren Hewitt as the ex-officio member for the 
Substance Abuse and Mental Health Services Administration. 
• Dr. Susan Robilotto and Ms. Marlene Matosky would serve as alternate ex-officio 
members for the Health Resources and Services Administration (HRSA) HIV/AIDS 
Bureau in the absence of Dr. Rupali Doshi. 
Dr. Dean asked the participants to join her in welcoming the new members, ex-officio members 
and liaison representatives to their first ACET meeting. 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole joined Dr. Dean in welcoming the participants to day 1 of the ACET meeting.  She 
explained that ACET would continue to address issues related to TB elimination.  She thanked 
the ACET members for contributing their valuable time and expertise to assist CDC in achieving 
this important national goal. 
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NCHHSTP Office of Director’s Report 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer (DFO) 
Dr. Dean covered the following topics in the NCHHSTP Office of Director’s (OD) report to 
ACET.  At the agency level, CDC, other U.S. government agencies, the World Health 
Organization (WHO) and international partners are continuing their response to the rapidly 
changing ebola outbreak in West Africa.  The ebola outbreak is the largest outbreak of this 
disease in history and has accounted for 5,689 deaths to date. 
As of December 1, 2014, 10,050 of the total 15,935 ebola virus disease cases were laboratory-
confirmed.  Guinea, Liberia and Sierra Leone have accounted for the vast majority of cases.  
The deployment of 259 CDC staff as of December 1, 2014 includes 89 staff throughout the 
United States, 2 staff to other countries with reported ebola cases, and 168 staff to West Africa 
for surveillance, contact tracing, data management, laboratory testing and health education.  
CDC also activated its Emergency Operations Center to coordinate ebola-related assistance 
with partners. 
CDC is operating under a continuing resolution that authorizes FY2015 appropriations through 
December 11, 2014 at the FY2014 enacted levels.  The continuing resolution also provides 
additional funding to support the ebola outbreak response in Africa, including $30 million to 
CDC’s global health programs. 
CDC established a new Laboratory Safety Improvement Workgroup in July 2014 that will be 
responsible for specific tasks.  The moratorium on the movement of biological material outside 
of Biosafety Level 3 and 4 Laboratories will be addressed.  The CDC Director will be advised on 
the resumption of transfers.  To date, 49 packages have been submitted for review of the 
moratorium on laboratory safety, 33 packages have been released, 12 packages have been 
released with provisions, 3 packages are under review, and 4 packages are pending 
submission. 
Laboratory safety recommendations will be implemented to address recent laboratory incidents 
at CDC.  Oversight will be provided of corrective actions and an inventory of biologic material in 
all CDC laboratories (i.e., a “Clean Sweep”).  Recommendations will be developed to establish a 
permanent single point of accountability for laboratory safety.  CDC recently released a job 
posting for a new Associate Director for Laboratory Science. 
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The workgroup primarily will focus on two major aspects of laboratory safety.  First, the use of 
protocols for key control points (e.g., pathogen inactivation) by trained and supervised staff will 
be demonstrated. Second, redundant control/secondary verification of critical control points will 
be established via direct observation by supervisors or staff and critical actions recorded on 
camera. 
At the National Center level, NCHHSTP is pleased to announce changes in its leadership at the 
OD level.  Dr. Philip LoBue was appointed as the new Director of the Division of Tuberculosis 
Elimination.  Dr. Eugene McCray was appointed as the new Director of the Division of HIV/AIDS 
Prevention (DHAP).  Dr. Richard Wolitski was appointed as the new Senior Advisor for Indicator 
Monitoring and Program Improvement. 
NCHHSTP deployed >125 staff to the ebola response over the past few months, including >40 
staff to Africa.  All NCHHSTP laboratories currently are active due to the release of three of its 
laboratories from the moratorium on the movement of biological material. 
NCHHSTP established three goals for its draft 2020 Strategic Plan.  The incidence of infection, 
morbidity and mortality, and health disparities across affected groups will be decreased for HIV, 
viral hepatitis, STDs and TB.  Efforts are underway to develop indicators, targets and strategies 
to measure progress on achieving the Strategic Plan goals.  NCHHSTP expects to finalize the 
draft Strategic Plan early in 2015. 
NCHHSTP published the latest edition of its State Health Profiles.  NCHHSTP launched a new 
policy web page for TB, HIV and STD prevention programs.  The new web page serves as a 
“one-stop shop” with tools and resources of legal assessments across all of NCHHSTP’s focus 
areas.  NCHHSTP hosted a Program Collaboration and Service Integration training session for 
public health officials in the U.S.-Affiliated Pacific Islands.  This event provided a platform to 
build capacity in these resource-limited areas. 
DTBE Director’s Report 
Philip LoBue, MD 
Director, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Dr. LoBue focused his Director’s report to ACET on strategies for TB elimination in the United 
States.  Since systematic recording of TB began in 1953, 2013 marked the fewest number of 
cases reported (9,582) and the lowest TB case rate (3.0/100,000).  However, a tremendous gap 
still exists between current TB morbidity and the elimination goal of ~300 cases (or a case rate 
of <0.1/100,000). 
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The key risk groups for TB have remained the same for over 10 years.  Foreign-born persons 
(FBPs) account for 63% of TB cases and have a case rate that is 11 times higher than in U.S.-
born persons.  China, India, Mexico, the Philippines and Vietnam account for the top five 
countries of the TB burden in FBPs.  Racial/ethnic minorities account for 84% of TB and have a 
case rate that is 7-17 times higher than in whites.  Other key risk groups for TB include HIV-
infected persons (~7%), homeless persons (~6%), incarcerated persons (~4%), and substance 
abusers (7%-12%). 
CDC identified several challenges to reaching the national TB elimination goal.  Political 
commitment has weakened as the number of cases continues to decrease.  Resources are at 
risk because TB is less of a priority to policymakers and the general public.  Clinical, laboratory 
and public health expertise and experience have been lost. 
Drug and biologic shortages are more problematic due to the lack of a market.  Regulatory 
requirements limit access to the Global Drug Facility (GDF) or other mechanisms for the larger 
global market.  Efforts are concentrated to the remaining cases and outbreaks in more difficult-
to-reach populations (e.g., FBPs and homeless persons).  Latent TB infection (LTBI) accounts 
for <10,000 TB cases, but the large pool of 11 million persons with LTBI needs to be addressed. 
The recent Hill study modeled TB trends in the United States and described actions that would 
need to be taken to reach the TB elimination goal of <1 case/1 million population.  The study 
showed that combining the two strategies of decreasing the LTBI prevalence among FBPs 
entering the United States and substantially increasing LTBI treatment would nearly reach the 
TB elimination goal. 
CDC’s position is that the 2000 Institute of Medicine (IOM) Report, Ending Neglect: The 
Elimination of Tuberculosis in the United States, still should guide current TB elimination efforts.  
CDC’s response to the report included six fundamental goals that are elements of a national 
elimination strategy.  Dr. LoBue described newer approaches CDC is considering to achieve the 
six TB elimination goals since the release of the IOM Report nearly 15 years ago. 
Goal 1 is to maintain control of TB.  Efforts for complete and rapid detection of persons with 
active TB disease are successful in the United States because all cases ultimately are located.  
Gene Xpert and other new technologies can assist in minimizing delays in case detection.  
Clinical decision support tools and other educational efforts also can help primary providers to 
“think TB” and order diagnostic tests for suspected cases.  A new, innovative approach would 
be to develop a multiplex test for TB and other respiratory infections that would not require 
providers to order a separate TB test. 
Current TB treatment is adequate to maintain high treatment completion rates among persons 
with active disease.  Shorter-course regimens are now being studied and would be particularly 
beneficial in lowering costs.  Several TB programs are using more efficient and effective video 
and wireless technologies to substantially decrease the cost of directly observed therapy (DOT).  
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However, CDC acknowledges that a large, rigorous evaluation study is needed before definitive 
recommendations can be made on the use of these technologies. 
Investigation, appropriate evaluation and treatment of contacts of infectious TB cases will 
continue to be important to goal 1 because up to 1%-2% of contacts have active disease.  The 
ability to detect and treat LTBI is limited because the tuberculin skin test (TST) and interferon-
gamma release assays (IGRAs) poorly predict persons who will develop TB in the future.  The 
specificity of IGRAs is weaker in some low-risk populations, but IGRAs are more beneficial in 
FBPs with Bacillus Calmette-Guérin (BCG) vaccination because only one visit is required.  
Short-course regimens will provide greater opportunities to improve treatment, such as the 3-
month, once-weekly Isoniazid/Rifapentine (3HP) regimen and the 4-month Rifampin regimen. 
Infection control measures have been effective in preventing transmission of TB in the United 
States, particularly in healthcare settings.  Healthcare-associated outbreaks of TB have not 
been reported since the 1990s, but more focus is needed on infection control and prevention 
measures in homeless shelters and correctional facilities.  These settings account for most of 
the recent TB outbreaks.  Initiatives to improve infection control standards in these settings 
include the DTBE Homeless Workgroup, the ACET and DTBE Corrections Workgroups, and 
DTBE’s ongoing collaboration with the Interagency Council on Homelessness. 
Goal 2 is to accelerate the decline of TB.  The primary focus should be placed on FBPs from 
medium- and high-incidence countries to improve targeted testing and treatment of persons with 
LTBI.  Because this pool of persons is extremely large and resources are limited, efforts initially 
should be targeted to the high priority subpopulation of FBPs who have the greatest risk of 
progression to active disease (e.g., FBPs with HIV or diabetes, FBPs who smoke, and FBPs on 
immune-suppressing drugs).  IGRAs should be used in BCG-vaccinated FBPs, while short-
course regimens should be used in all persons with LTBI to increase completion rates. 
Due to limited resources that are not expected to increase in the near future, testing and 
treatment should be expanded beyond health departments.  CDC has identified three potential 
strategies in this effort:  (1) leverage resources from the Affordable Care Act (ACA); (2) conduct 
LTBI testing in primary care settings for at-risk groups and obtain reimbursement for this service 
based on a U.S. Preventive Services Task Force (USPSTF) Grade A or B recommendation; and 
(3) scale-up successful program models that have identified and extensively engaged service 
providers of target populations in the community. 
CDC-funded RTMCCs can continue to be used to assure appropriate regionalization of TB 
control activities.  CDC is developing a Laboratory Center or Excellence to increase the 
availability of high-quality drug susceptibility testing, particularly in low-incidence jurisdictions 
that cannot maintain proficiency.  Genotyping is nationalized and completed by one laboratory 
for the entire country.  Legal and practical challenges will need to be addressed to expand 
regional approaches when the number of TB cases decline even further. 
 
Minutes of the Meeting 
Advisory Council for the Elimination of Tuberculosis 
December 2-3, 2014  ♦  Page 8 
 
Rapid outbreak response is essential to interrupt transmission of TB.  Homeless persons, 
substance abusers and incarcerated persons account for the vast majority of recent outbreaks.  
Universal genotyping has facilitated earlier recognition of TB transmission and earlier response 
to outbreaks because alerts have been incorporated into the genotyping database.  More 
knowledge and understanding of predictors of the growth of TB clusters have increased the 
ability to prioritize clusters and more rapidly respond to outbreaks.  However, implementation of 
infection control and prevention measures in homeless and correctional settings needs 
tremendous improvement. 
Goal 3 is to develop new tools for the diagnosis, treatment and prevention of TB.  Efforts are 
underway to identify the most effective approaches to implement new tools:  IGRAs, Gene 
Xpert, the feasibility of overcoming barriers to DOT in order for patients to self-administer 3HP, 
the role and utility of whole-genome sequencing in genotyping, molecular detection of drug 
resistance for other drugs beyond Gene Xpert, and Bedaquiline (BDQ) and Delamanid for 
multidrug-resistant-TB (MDR-TB). 
New drugs and regimens are in various stages of development, including 4-month shorter-
course regimens for drug-susceptible TB, a 9-month regimen for MDR-TB, and new tests for 
diagnosis and detection of drug resistance.  Despite these advances, basic research funded by 
the National Institutes of Health (NIH) and Gates Foundation is needed to achieve broader, 
more transformative changes. 
• An LTBI test that is highly predictive of persons who would progress to active TB 
disease 
• Inexpensive and simple point-of-care tests to diagnose TB disease and detect drug 
resistance, particularly for global TB control 
• Ultra-short regimens with a duration of no more than 4 weeks for TB disease and LTBI 
treatment to increase completion rates to nearly 100% and reduce cost 
• A highly effective TB vaccine 
Goal 4 is to reduce the global burden of TB by increasing U.S. involvement in international TB 
control activities.  Support should continue to be provided to WHO and other global or 
multilateral organizations in developing evidence-based policy.  Strategic partnerships should 
be established with individual countries.  Emphasis should be placed on countries that overlap 
in terms of their high TB burden and significant contributions to domestic TB cases among their 
immigrants who enter the United States.  A transition should be made from short-term projects 
that originate from CDC in Atlanta to longer-term, in-country technical assistance to increase 
impact.  The strong focus on TB drug resistance and HIV should continue due to their greater 
role globally. 
CDC’s current overseas screening program of persons entering the United States has been 
extremely effective in detecting and treating TB disease in permanent immigrants and refugees.  
Most foreign-born TB cases occur from reactivation of LTBI after their residence in the United 
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States for several years.  CDC is considering the feasibility of incorporating LTBI testing and 
treatment with short-course regimens into the current overseas screening program and 
expanding screening to include other long-term visitors (e.g., students and work visa recipients). 
Goal 5 is to mobilize and sustain support for TB elimination by engaging policy and opinion 
leaders, healthcare providers, affected communities and the general public.  CDC will enhance 
its existing partnerships with both domestic and international organizations to ideally increase 
support for TB elimination.  CDC currently is conducting a “cases-averted” analysis to make a 
stronger argument.  For example, >200,000 TB cases have been averted since the response to 
the TB resurgence in the 1980s-1990s.  Other initiatives CDC is considering to increase support 
for TB elimination include quantifying cost-savings and benefits, documenting the return on 
investment, and conveying powerful stories from individual TB patients. 
Goal 6 is to monitor progress toward reaching the TB elimination goal and regularly report on 
progress to all target audiences.  CDC currently uses outcome and process measures in the 
National Tuberculosis Indicators Project to track overall progress, but improvements will be 
made in the future to better evaluate individual TB elimination projects and programs.  The 
performance of funded TB programs and laboratories will be assessed on a regular basis.  The 
DTBE Research Workgroup recommended periodic internal and external reviews of research 
projects.  Approaches are needed to compile key outcomes from these evaluation processes to 
demonstrate improvement.  The National TB Program objectives and performance targets for 
2015 were displayed for ACET’s review. 
Dr. LoBue concluded his update by summarizing the five key strategies for TB elimination in the 
United States. 
1. Sustain commitment 
• Utilize critical partnerships 
• Make a strong argument by documenting the return on investment and conveying 
stories of persons affected by TB 
2. Maintain basic TB control functions 
• Improve the effectiveness and efficiency of TB case finding and treatment, contact 
investigations and infection control 
3. Expand effective LTBI testing and treatment 
• Broaden efforts beyond health departments 
• Target FBPs as a high priority population 
• Implement new TB regimens and tools 
4. Strategically engage in global TB efforts 
• Maximize the impact of limited resources because the national TB elimination goal 
cannot be achieved without more progress globally 
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5. Minimize the difficulties and complexities associated with TB control 
• Promote and take advantage of scientific and technological advancements 
ACET agreed with Dr. LoBue that three key areas must be prioritized in order to achieve the TB 
elimination goal in the United States:  TB in FBPs, TB in correctional settings, and global TB 
efforts.  ACET discussed the following topics with Dr. LoBue in this regard.  
• The need to revise strategy 4 to describe funding and other efforts by CDC and its 
partners in the Global TB Strategic Plan. 
• The extent to which TB elimination continues to be a “motivational” or “inspirational” 
factor for the nation. 
• The need to shift messaging to focus more on the larger pool of 11 million persons with 
LTBI rather than the smaller number of <10,000 TB cases attributed to LTBI. 
• The role of ACA in TB elimination. 
• CDC’s rationale for not finalizing, clearing and releasing ACET’s Foreign-Born TB 
Guidelines. 
• CDC’s difficulties in updating the Report of Verified Case of Tuberculosis. 
• The need to build strong relationships with diabetes national organizations and engage 
these groups as key partners in TB elimination, particularly since current diabetes 
guidelines do not mention TB and diabetes/TB co-infection is as high as 15% in some 
jurisdictions. 
Overview of NCHHSTP’s Health Equity Activities 
Wayne Duffus, MD, PhD 
Associate Director for Health Equity 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
Advice Requested from ACET by the NCHHSTP Office of Health Equity (OHE): 
• What are the essential issues for TB elimination that should be considered when 
developing training and educational materials aimed at increasing knowledge of health 
equity concepts? 
• What key issues other than funding should be addressed to achieve health equity for TB 
elimination at state and local levels? 
• What specific strategies should be operationalized to achieve health equity for TB 
elimination? 
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Dr. Duffus presented an overview of NCHHSTP’s health equity activities.  NCHHSTP’s vision is 
“a future free of HIV, viral hepatitis, STDs and TB” and its mission is to save lives, protect 
individuals and reduce disparities associated with these diseases.  NCHHSTP’s three goals in 
the draft 2020 Strategic Plan are aligned with its vision and mission.  The incidence of infection, 
morbidity and mortality, and health disparities across affected groups will be decreased for HIV, 
viral hepatitis, STDs and TB. 
NCHHSTP adopted the definition of “health equity” as optimal health for all with no persons 
being disadvantaged from achieving this potential because of their socially determined 
circumstances.  Regardless of age, gender, race/ethnicity, income, education, geographic 
location, disability or sexual orientation, all persons in every community across the nation 
deserve equal access to their best health.  “Health inequity” is defined as the difference or 
disparity in health outcomes that is systematic, unfair and avoidable. 
A holistic approach to reducing the rates of HIV, viral hepatitis, STDs, TB and other diseases is 
needed in order to ensure all persons have an opportunity to achieve optimal health.  In addition 
to individual and behavioral factors, environmental and social factors also must be addressed 
(e.g., education, housing, access to employment and transportation).  NCHHSTP adopted and 
modified the WHO Conceptual Framework on Social Determinants of Health (SDH) to better 
understand common conditions and health inequities in its target populations that negatively 
impact health outcomes. 
The SDH model demonstrates that adults with a higher level of education are likely to live 
longer.  College graduates are likely to live at least 5 years longer than non-high school 
graduates.  Adult life expectancy also increases with a higher level of income.  Adults in the 
highest income groups are likely to live at least 6.5 years longer than adults in poverty.  Lower 
positions are associated with worse health, while higher positions are associated with better 
health.  Compared to white adults, for example, poor or fair health is much more common in 
black and Hispanic adults due to lower incomes in these populations. 
The SDH model further illustrates the impact of residential segregation on access to care or 
high-quality care.  Moreover, food deserts in specific communities limit the ability of residents to 
access fresh fruits and vegetables that are necessary for a balanced diet.  Homelessness and 
correctional systems might be associated with higher rates of mental health and substance 
abuse.  The prevalence of HIV/STD infections in some communities might place persons at risk 
without an actual increase in their individual risk behaviors. 
The health impact pyramid describes different types of public health interventions and provides 
a framework to improve health.  The five tiers of the pyramid from the lowest to highest level are 
socioeconomic factors, contextual changes to make individuals default to healthy decisions, 
long-lasting protective interventions, clinical interventions, and health counseling and education.  
Interventions at the lower levels of the pyramid are more effective in increasing population-
based impact, while interventions at the higher levels are less effective because more individual 
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participation and behavioral changes are required on an ongoing basis.  However, the 
implementation of interventions at each level can achieve and sustain public health benefits to 
the maximum extent possible. 
In addition to the NCHHSTP’s center-wide OHE and Health Equity Workgroup, DHAP and the 
Division of STD Prevention also have an OHE as part of their organizational structures.  
Moreover, DTBE appointed a new Health Equity Coordinator earlier in 2014 to promote health 
equity concepts in research, policy and programs.  NCHHSTP also supports a number of cross-
center workgroups to address health equity in priority populations and settings, including 
corrections, drug users, youth and men who have sex with men. 
The NCHHSTP Office of Health Disparities was established in 2003 and eventually was re-
branded as the current “Office of Health Equity.”  Several notable accomplishments have been 
made since that time.  A “Lunch and Learn Health Equity Scientific Lecture” is held on the third 
Thursday of each month.  These events are well received and accounted for >400 participants 
in FY2014.  The lecture series has featured several TB-related presentations over the past two 
years, particularly TB disparities in African Americans and TB in homeless populations. 
NCHHSTP celebrated the 10th anniversary of OHE in November 2013 with the theme, “From 
Theory to Action: Applying Social Determinants of Health to Public Health Practice.”  
Distinguished keynote speakers and other stakeholders highlighted the role of public health in 
reducing health inequities, shared key accomplishments, and facilitated discussions on 
strategies to advance health equity efforts. 
NCHHSTP published three supplements in Public Health Reports in 2010-2013.  The papers 
focused on SDH in the prevention and control of HIV/AIDS, viral hepatitis, STDs and TB; data 
systems and SDH; and the application of SDH to public health practice.  NCHHSTP’s 2014 
publications in peer-reviewed journals focused on health equity among incarcerated female 
adolescents and adult women, HIV/STD risks for young blacks in high prevalence areas, and 
training to racial/ethnic minority students for careers in public health sciences.  Dr. Jonathan 
Mermin, Director of NCHHSTP, was a keynote speaker at the 2014 Conference on Correctional 
Health Care and described HIV/AIDS, viral hepatitis, STDs and TB in correctional settings. 
NCHHSTP revised its existing policies to ensure that health equity is an overarching goal in the 
center-wide Strategic Plan.  NCHHSTP’s 2010 SDH white paper highlighted public health 
approaches to eliminate health disparities in HIV/AIDS, viral hepatitis, STDs and TB in the 
United States.  NCHHSTP increased the number of funding opportunity announcements with 
health equity and SDH language from 20 in FY2012 to 55 in FY2014. 
NCHHSTP has, currently is and will continue to identify and address key SDH issues for 
programs.  Completed initiatives include launching the SDH web page on the CDC.gov website 
in 2009; releasing the 2013 SDH Activities Report; and publishing the HIV/AIDS, Other Sexually 
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Transmitted Diseases, Viral Hepatitis and TB in State and Federal Prisons Report in the spring 
of 2014. 
Ongoing initiatives include the dissemination of various communication products:  health equity 
and SDH glossary of terms, SDH frequently asked questions, press releases and surveillance 
reports.  Future initiatives include the provision of training and educational resources (e.g., slide 
sets and webinars) to internal and external partners to increase their knowledge of health equity 
concepts.  Moreover, Centers for Medicare and Medicaid data for all 50 states will be used to 
conduct analyses and develop research questions related to SDH. 
NCHHSTP maintains a strong and diverse group of partnerships to conduct its health equity 
activities.  These partnerships include federal agencies and academic institutions; public health 
ethics, health equity and sexual health experts; fellowship programs; and national organizations 
with a disease-specific focus on HIV, viral hepatitis, STDs and TB.  NCHHSTP also targets 
recruitment efforts to racial/ethnic minorities to ensure that this student population considers 
public health as a top career choice.  Moreover, NCHHSTP attempts to include health equity 
issues when new curricula are developed. 
NCHHSTP will conduct its first health equity site visit with stakeholders for HIV, viral hepatitis, 
STD and TB prevention on December 4-5, 2014 in Tennessee.  NCHHSTP will aim to achieve 
several learning objectives for staff. 
• Understand barriers to achieving health equity in Tennessee from the perspectives of 
persons who live and work in the state. 
• Identify new and existing activities to increase health equity between advantaged and 
disadvantaged populations. 
• Understand Tennessee’s process to establish priorities; allocate state, local and private 
resources among social groups with disproportionate levels of need; and determine 
adverse health outcomes in the context of current national programs and priorities. 
• Identify Tennessee’s innovative approaches to improve healthcare access and address 
the impact of preventive services in a non-Medicaid expansion state. 
Dr. Duffus encouraged ACET to obtain additional information on health equity from websites of 
the WHO Commission on Social Determinants of Health, the HHS Healthy People 2020 
Initiative, and the Robert Wood Johnson Foundation. 
ACET discussed the following topics with Dr. Duffus on NCHHSTP’s health equity activities 
related to TB. 
• The need for NCHHSTP to include “country of origin” as an additional characteristic in its 
health equity definition. 
• The feasibility of NCHHSTP examining inadequate vitamin D levels as a health disparity 
for TB and LTBI, particularly in African Americans. 
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• NCHHSTP’s efforts to engage, partner with and provide education to national provider 
and healthcare organizations that serve African Americans and Hispanics, particularly 
since TB/diabetes co-infection disproportionately impacts these minority populations. 
Panel Presentation: Perspectives from the Field on the Status of TB Elimination 
A panel of ACET liaison representatives described perspectives from the field on the status of 
TB elimination in the United States. 
Robert Benjamin, MD, MPH 
Deputy Health Officer, Marin County Department of Health and Human Services 
Chair, Stop TB USA and  
ACET Liaison Representative, National Association of County and City Health Officials 
Advice Requested from ACET by Stop TB USA: 
• Will ACET resolve to reaffirm and endorse the 2010 TB Elimination Plan 
recommendations? 
• Will ACET strongly encourage HHS and CDC to implement the 2010 TB Elimination Plan 
recommendations and ask the Federal TB Task Force to present an updated overview? 
• Will ACET perform periodic assessments and submit progress reports to HHS as 
recommended in the original TB Elimination Plan? 
• Will ACET members convey TB messages to their individual organizations? 
• Do ACET members expect their individual organizations to partner with Stop TB USA and 
the National Tuberculosis Controllers Association (NCTA)? 
Dr. Benjamin presented an update on the “Call for Action on the Tuberculosis Elimination Plan 
for the United States.”  Stop TB USA initiated the Call for Action by convening a retreat with 
CDC, NTCA and other TB partners in August 2007.  The participants extensively reviewed 
recommendations in the 2000 IOM Report to determine the need for a new document.  The 
participants discussed the five goals in the IOM report to begin fulfilling its charge: 
• Maintain TB control despite the decline in the number cases 
• Accelerate the decline in TB by increasing targeted testing and treatment of LTBI 
• Develop new diagnostic, treatment and prevention tools for TB 
• Increase U.S. involvement in global TB control 
• Mobilize and sustain public support for TB 
The participants agreed that despite the passage of seven years between the release of the 
IOM report in 2000 and the Stop USA retreat in 2007, the recommendations were still valid.  
However, the participants noted that the IOM recommendations had not been fully implemented.  
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The participants reached consensus on updating the IOM report with a newer TB elimination 
plan that would focus more on the involvement of stakeholders in TB elimination efforts in the 
United States and describe specific action steps to implement the IOM recommendations.  The 
participants agreed that the following stakeholders should be engaged:  policymakers at all 
levels of government, the public health sector, medical practitioners, professional societies, 
community-based organizations (CBOs) and voluntary organizations. 
Stop TB USA’s 2010 TB Elimination Plan serves as a realistic appraisal of the current status of 
TB elimination efforts in the United States and includes a description of unique challenges to 
specific populations.  ACET provided advice during the development of the report and formally 
endorsed the final document that was released in 2010. 
The executive summary of the 2010 Elimination Plan notes that recent trends have prompted 
the reevaluation of national plans and efforts for TB elimination in the United States.  Several 
points are emphasized in this regard.  TB remains a serious and persistent threat to health in 
communities throughout the country.  Interim targets for TB elimination have not been met.  The 
rate of decrease in TB incidence is slowing, but not accelerating.  TB elimination will require 
nearly 100 years if the current trends continue. 
The 2010 TB Elimination Plan summarizes whether Stop TB USA’s previous recommendations 






Maintain public awareness of the threat of TB and the importance of TB 
elimination through collaborative efforts among Stop TB USA, partners and 
other stakeholders 
Yes 
Renew and/or expand the commitment to TB elimination in the United States, 
including adequate resources and funding 
No 
Fully engage partners and stakeholders to assure that all U.S. citizens are 
provided with timely access to lifesaving TB services for the diagnosis, 







Make a commitment to implement the 2000 IOM recommendations and 
conduct a periodic review on the progress toward TB elimination 
Uncertain 
Develop new timelines and interim goals for TB elimination Uncertain 
Obtain assistance from various organizations to leverage infrastructure 
funding that would enable Stop TB USA to collaborate with CDC and other 
partners in generating political will to implement the 2000 IOM 
recommendations and action plans 
Uncertain 
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Address the federal funding gap by obtaining an independent assessment of 
the extent to which increased funding levels authorized in the 
Comprehensive Tuberculosis Elimination Act of 2007 effectively could 
accelerate the development and implementation of new tools for the 
diagnosis, treatment and prevention of TB 
No 
Engage policymakers at federal, state and local levels, the public health 
sector, medical practitioners, professional societies, CBOs and voluntary 
organizations in a commitment to TB elimination 
Yes/No 
The 2010 TB Elimination Plan conveys several key messages.  The plan to eliminate TB in the 
United States failed and is projected to require over 90 years.  The failure to implement the U.S. 
plan leaves TB and drug-resistant TB as a growing, yet largely ignored global microbial threat.  
Major advances in diagnostics have been made, but implementation of these tools has been 
slow.  Current TB treatment regimens are weak, poorly tolerated and toxic.  Major governmental 
funding will be required. 
The 2010 TB Elimination Plan describes specific action steps.  Action step 1 is to develop new 
long-term objectives.  Stop TB USA’s new long-term strategic plan includes two objectives and 
timelines that are aligned with those in the WHO Global TB Program Framework Toward TB 
Elimination in Low-Incidence Countries. 
Objective 1 is to eliminate TB in the United States by 2050 as defined by <1 case/1 million 
population and no TB deaths.  Interim milestones have been established for 2025 and 2035 to 
reduce TB deaths, decrease TB incidence, and assure that no families are affected by 
catastrophic costs related to TB.  Objective 1 will require a marked increase in funding for TB 
research and development; ongoing funding by federal, state and local governments and other 
industrialized countries; and a commitment to meet public health infrastructure needs.  
Objective 2 is to collaborate with the Global Stop TB Partnership to leverage adequate funding 
to produce three safe and effective short-course regimens for all TB patients regardless of prior 
drug-resistance patterns by 2035.  Interim milestones have been established for 2020, 2025 and 
2035 to increase research and development funding to within 75% of the World Health 
Assembly goal of $2 billion per year, ensure the safety and efficacy of a new MDR-TB regimen, 
and assure the availability of three safe and effective regimens for all TB patients. 
Action step 2 is to support policy and education efforts.  Funds authorized in the TB Elimination 
Act should be appropriated.  State and local public health funding for TB control should be 
maintained.  Membership on the U.S. House of Representatives TB Caucus should be 
increased from 38 representatives. 
Action step 3 is to consider TB in the context of public health preparedness.  The HHS 
Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, 
systematic approach to the development and purchase of necessary vaccines, drugs, therapies 
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and diagnostic tools for public health medical emergencies.  Stop TB USA is now represented 
on the new national stakeholder group on antimicrobial resistance. 
The failure to rapidly develop and implement new tools for the diagnosis and treatment of TB 
and LTBI has left state and local health departments inadequately prepared for MDR-TB and 
entirely unprepared for extensively drug-resistant TB (XDR-TB).  Continued occurrence of MDR-
TB outbreaks in communities should be widely publicized. 
Action step 4 is to identify visionary leadership for drug-resistant TB.  WHO should partner with 
the International Labour Organization (ILO) to ensure a healthy, productive and TB-free 
workforce that migrates throughout the world. 
Action step 5 is to elevate TB as a national priority for funding.  For example, NIH allocated 
~$2.9 million to HIV/AIDS research and $207,000 to TB research in 2013.  The Global Plan 
annual targets for TB research funding have not been met in the areas of basic science, new 
diagnostics, new drugs, new vaccines and operational research.  The purchasing power of 
CDC’s annual TB budget has decreased by 52% from FY1990 to FY2014. 
The Gates Foundation recently committed $258.3 million to malaria research and development, 
but similar philanthropic funding has not been allocated to TB.  HHS recently announced that 
$2.2 billion in grants would be supported by the HRSA-funded Ryan White HIV/AIDS Program 
for care and medications.  The new grants will support efforts to achieve the goal of an AIDS-
free generation, but similar federal funding has not been allocated for a “TB-free generation.” 
Action step 6 is to change TB-related messaging.  Most notably, the word “latent” should be 
removed from the term “latent TB infection.”  Recent scientific research into the nature and 
dynamics of granulomas reveals that there is nothing “latent” about granulomatous lesions.  In 
addition, because the term “latent” implies that it is not serious, the term has become politically 
ineffective and adversely impacts the ability to leverage and increase funding for TB. 
Action step 7 is to identify new partners and strengthen existing partnerships.  A larger and 
stronger pool of partners might influence CDC to include TB in its list of “winnable battles.” 
John Bernardo, MD 
Professor of Medicine and Biochemistry, Boston University School of Medicine 
ACET Liaison Representative & President, National Tuberculosis Controllers Association 
Dr. Bernardo described perspectives from NTCA and the nation’s TB control programs on the 
status of TB elimination in the United States.  NTCA is a professional organization of TB 
program staff that represents all TB workers regardless of their NTCA membership.  NTCA 
derived its name because of the role of state and large-city TB controllers as the decision-
makers for their respective jurisdictions. 
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NTCA’s strategic planning process in 2013 resulted in defining its vision as “a world free of TB” 
and clarifying its mission “to protect the public’s health by advancing the elimination of TB in the 
United States through concerted actions of state, local and territorial government programs.”  
NTCA is aware that the focus should be placed on four key areas to better understand TB 
elimination in the United States. 
First, “domestic TB elimination” should be clearly defined.  A clear distinction should be made 
between goals that can and cannot be achieved.  Second, various strategies should be 
identified due to differences between public health and community priorities.  Implementation 
plans described in the “Essential Elements of TB Control” should continue to serve as valid 
resources.  Third, infrastructure needs at multiple levels should be addressed, including 
geographic, cultural, clinical and scientific factors.  Fourth, the fiscal base should be specified in 
terms of direct patient costs, infrastructure costs and ACA. 
The Essential Elements of TB Control include overall planning and policy, management of TB 
cases and suspects, identification of persons with TB disease, identification and management of 
persons infected with Mycobacterium tuberculosis, laboratory and diagnostic services, data 
collection and analysis, and training and education. 
A major challenge in TB elimination efforts is the perception among Congressional staff that TB 
is no longer a problem in the United States.  TB has markedly declined over the past 30 years, 
but 9,588 cases were reported in 2013.  Los Angeles, Fulton County, Georgia and Springfield, 
Massachusetts reported 113 TB cases that were linked to homeless populations in 2008-2014.  
Of the 94 TB cases reported by Los Angeles and Georgia, 14 resulted in deaths. 
Massachusetts identified significant health disparities in 201 TB cases reported in 2013.  Case 
rates were 0.8/100,000 in whites, 19.1/100,000 in Asians, 13.6/100,000 in African Americans, 
and 4.9/100,000 in Hispanics.  Foreign-born residents of the state represent >50 countries each 
year and have accounted for >80% of TB cases in Massachusetts since 2011. 
Access requires engagement at multiple sectors.  Engagement of the public includes at-risk 
communities and the population at large.  The language, fears, priorities, needs, health beliefs 
and health-seeking behaviors of the community should be understood, particularly since these 
factors typically are discordant with clinical and public health views on the diagnosis, prevention 
and treatment of TB. 
Public health messaging should address personal concerns, stigma, and financial fears related 
to healthcare costs and the potential loss of employment.  Trusted and credible sources for the 
community to obtain health information should be identified (e.g., pharmacists, non-traditional 
practitioners, CBOs and faith-based organizations).  The best method to communicate with the 
community should be determined (e.g., printed materials and radio advertisements). 
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Public health messaging should be designed to engage at-risk communities.  Dialogue should 
be initiated to build trust with the community.  Access to public health services should be 
provided on the community’s terms.  Effective community engagement will result in access to 
reliable information and services, better understanding of TB and public health, and improved 
public and personal health. 
Engagement of health providers includes direct care providers and public health.  Direct care 
providers typically have poor understanding of and limited information on the epidemiology of 
TB in their patient populations and jurisdictions.  TB education and training are lacking in 
medical/nursing schools and residency/fellowship programs.  TB frequently competes with many 
other priorities in clinical settings.  Resources are limited for TB radiography, laboratory and 
community outreach services. 
Direct care providers should be identified for groups that are at risk for TB.  Healthcare systems 
should be engaged to determine TB needs, resources and expertise in the provider community.  
Evidence-based and credible educational programs should be offered to build competency in 
TB.  Educational strategies should be adapted to meet local needs, such as academic detailing 
in emergency departments, rotations of infectious disease grand rounds to medical students 
and residents, and workshops.  TB experts should be available to assist direct care providers. 
TB programs are unique in clinical and public health domains, but are being integrated into 
other public health department programs.  Public health services are considered to be no longer 
needed due to the inaccurate assumption that all persons are covered by private insurance or 
Medicaid.  Resources are needed to support the unique needs of the TB infrastructure, but 
public health decision-makers have competing priorities and legislators are unaware of 
problems and needs related to TB. 
Engagement of policymakers includes those at both national and jurisdictional levels.  The 
public should be educated to raise awareness of TB as both an individual and public health 
problem and generate public support.  Legislators should be engaged to encourage and support 
federal and local funding for categorical TB functions and programs.  Alliances should be 
established and strengthened with CBOs to support joint public health efforts. 
Access to TB services should be assured to develop trust and remove social, behavioral and 
financial barriers.  The TB infrastructure should be maintained by interacting and collaborating 
with programs to foster understanding of the unique needs of TB control in public health.  Cross-
jurisdictional strategies should be developed to assure compliance with the Essential Elements 
of TB Control, particularly clinical, laboratory and public health competencies. 
The TB infrastructure is in jeopardy at this time due to the reduced incidence of disease.  TB is 
now restricted to disadvantaged populations that account for the majority of morbidity.  TB 
programs have less staff in the field.  Cuts to TB funding appear to be based on perceptions 
rather than the realities of ACA.  The aging TB workforce continues to lose medical, nursing and 
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laboratory expertise.  A strong alliance with CDC, NIH and other federal partners is needed to 
emphasize the need for TB prevention in high-risk populations. 
Poor TB tools have been developed and scientific understanding of the organism-host 
relationship continues to be limited.  Clinical and translational TB research is difficult to conduct.  
The ability to generalize TB research findings outside of laboratory settings is difficult.  Relevant 
TB clinical trials are lacking and often are redundant.  Minimal attention has been given to TB 
drug alternatives and drug development.  The focus on antibiotics has increased resistance to 
TB drugs. 
FDA Panel Presentation: TB Drug Shortages 
A panel of speakers from the U.S. Food and Drug Administration (FDA) presented overviews on 
TB drug shortages. 
David Roeder 
Associate Director for Regulatory Affairs, Office of Antimicrobial Products 
U.S. Food and Drug Administration 
Mr. Roeder described the FDA approval process for non-U.S.-based manufacturers.  FDA 
ensures that safe and effective drugs are available in adequate supplies for the long-term to 
treat TB patients in the United States.  However, FDA faces two key challenges in this effort:  
(1) the ability to maintain older TB drugs on the market and (2) and the provision of effective 
incentives to encourage the development of new TB therapies. 
Most of the current FDA-approved TB therapies are older, off-patent drugs with a limited market 
in the United States.  Many TB drugs are approved and available in other countries.  Foreign 
manufacturers might not have sufficient experience with the U.S. drug regulatory system.  The 
three key factors that should be considered for FDA drug approval are highlighted below. 
Factor 1 is regulatory considerations.  A 505(j) application is for generic drug approval.  The 
application is submitted as an abbreviated new drug application (ANDA) to copy an already-
approved drug.  The generic drug and already-approved drug must have the same ingredients, 
route of administration, dosage form, strength, and conditions of use recommended in labeling.  
An ANDA must be submitted to FDA with manufacturing information, bioequivalence study 
results, labeling and administrative documents (e.g., patent certification). 
A 505(b)(2) application is submitted as a new drug application (NDA) to change an already-
approved drug that might require additional studies to fully establish safety and efficacy.  An 
NDA does not qualify for submission as a generic drug.  The applicant neither owns nor has a 
right of reference to all information necessary to support approval, but the literature or FDA’s 
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previous approval of another drug can be used.  A new dosage form or new combination 
product (e.g., fixed dose or co-package) likely would be a 505(b)(2) NDA for TB drugs. 
A 505(b)(1) full application is submitted as an NDA.  TB drugs, such as BDQ, typically require a 
new molecular entity. The applicant either owns or has a right of reference to all information 
necessary to support approval.  New molecular entities likely would be regulated as 505(b)(1) 
NDAs for TB drugs. 
Factor 2 is scientific considerations.  An ANDA requires bioequivalence studies unless a waiver 
is granted.  A 505(b)(2) NDA requires all studies necessary to support the change from the 
already-approved drug.  A 505(b)(1) NDA requires all studies necessary to support the safety 
and efficacy of the drug. 
Factor 3 is economic considerations.  ANDAs are charged user fees under the Generic Drug 
User Fee Act.  The fees are highly variable and primarily are influenced by the number of both 
domestic and foreign manufacturing facilities.  The law has no provisions for waivers or fee 
reductions.  ANDA user fees could range from $100,000 to $500,000, plus an annual fee for one 
facility at a cost ~$270,000, plus fees for post-market changes at a cost ~$32,000. 
NDAs are charged user fees under the Prescription Drug User Fee Act, but waivers can be 
obtained for orphan drugs, small businesses with <500 employees, drugs with a public health 
necessity, and barriers to innovation.  User fees for NDAs or Biologics License Applications 
(BLAs) can cost ~$2.3 million if clinical data are required, ~$1.2 million if clinical data are not 
required, or ~$1.2 million for supplements if clinical data are required; plus an annual fee for 
establishments at a cost of ~$569,000; plus an annual fee for products at a cost of ~$110,000.  
However, these fees likely would be waived for TB drugs that qualify as orphan drugs. 
Mr. Roeder highlighted the President’s Emergency Plan for AIDS Relief (PEPFAR) as a case 
study in using FDA’s existing regulatory framework to address urgent public health needs.  Most 
U.S. antiretroviral drugs were still under patent and were too expensive to use in PEPFAR when 
the program was launched in 2004.  Generic copies of these drugs could not be approved in the 
United States until the existing patents had expired.  Foreign generic products were available at 
a low cost, but their quality was unknown.  A pathway was sought to allow FDA oversight of 
product quality for the purchase of foreign generic products to be used in PEPFAR. 
Foreign firms submitted generic and 505(b)(2) applications with a goal of obtaining “tentative 
approval” from FDA.  Tentative approval allows FDA to review applications in their entirety to 
ensure standards for approval are met prior to the expiration of innovator patents.  Because 
tentatively approved drugs cannot be marketed in the United States, these products do not 
compete with innovators in the U.S. market.  However, tentatively approved drugs could be 
purchased for use in overseas PEPFAR programs with an assurance that the products meet 
FDA standards.  To date, 179 antiretroviral products, including new combination products and 
pediatric dosing forms, have been approved or tentatively approved for use in PEPFAR. 
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Monetary incentives are available to develop new TB therapies.  Incentive 1 is orphan drug 
designation and exclusivity.  This incentive is for diseases affecting <200,000 persons in the 
United States.  Orphan designation provides grants and tax incentives for drug development.  
An orphan drug is eligible for marketing exclusivity for seven years at the time of approval, but 
this incentive is not relevant to generic drugs. 
Incentive 2 is tropical disease priority review vouchers (PRVs).  This incentive is authorized by 
the FDA Amendments Act of 2007 and provides a list of eligible tropical diseases, including TB.  
Sponsors of applications for a new molecular entity for treatment of TB can be eligible for a PRV 
at the time of approval.  The owner of a PRV can use this incentive to obtain a priority review for 
any NDA or BLA.  Priority reviews can shorten the time of an NDA or BLA review by four 
months.  A PRV can be sold on the open market for use by another sponsor.  A recent sale of a 
PRV was $125 million. 
Incentive 3 is the Generating Antibiotic Incentives Now legislation.  Antibacterial and antifungal 
drugs, including TB drugs, that are intended to treat a serious or life-threatening infection can be 
granted a Qualified Infectious Disease Product (QIDP) designation.  Drugs with QIDP 
designation are eligible for fast-track designation, while NDAs for drugs with QIDP designation 
are eligible for priority review.  At the time of approval, drugs with QIDP designation are eligible 
for a five-year extension of any exclusivity granted with that approval.  As of November 21, 
2014, 62 QIDP designations have been granted. 
CAPT Jouhayna Saliba, PharmD 
Team Leader, Drug Shortage Staff, Center for Drug Evaluation and Research 
U.S. Food and Drug Administration 
Dr. Saliba described FDA’s role and response in addressing drug shortages.  FDA established 
its Drug Shortage Staff (DSS) in 1999 due to a shortage of Isoniazid (INH).  The overarching 
responsibility of DSS is to facilitate the prevention and resolution of shortages by collaborating 
with key stakeholders from FDA, other government agencies, industry and the public. 
FDA collects drug shortage data from multiple sources across the supply chain.  The FDA 
Safety and Innovation Act (FDASIA) was enacted in July 2012 and requires manufacturers to 
notify FDA about the potential for disruption in the supply of any drug for any reason six months 
in advance.  However, FDASIA does not require reporting of drug shortage data from all points 
in the supply chain.  Other data sources include voluntary information submitted by industry, 
FDA staff in the field, and reports from individual members of the public. 
FDA requires notification by manufacturers of interruptions in the supply that could lead to a 
meaningful supply disruption or discontinuation as well as any changes in manufacturing.  FDA 
sends a letter to manufacturers that do not comply with notification requirements.  Although a 
monetary penalty is not imposed, non-compliance letters are posted on the FDA website for 
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public viewing.  FDA cannot require a company to manufacture a drug, increase its drug supply, 
or target distribution of a drug to specific populations or jurisdictions. 
The number of drug shortages reported to FDA decreased from 251 in 2011 to 44 in 2013.  In 
2013, sterile injectables (e.g., chemotherapy, anesthesia and other acute medications) 
accounted for 80% of shortages.  This is due to the complex, highly-specialized manufacturing 
process of these products.  A manufacturing process that is not meticulous could pose a high 
risk to patients.  A shortage of sterile injectables is likely if quality or production problems arise 
with these products.  In 2013, oral solid drugs account for 18% of shortages.  The top three 
factors for drug shortages in 2013, are quality issues related to manufacturing (37%), quality 
issues related to delays and capacity (27%), and raw materials (27%). 
The HHS Assistant Secretary for Planning and Evaluation released a report in 2011 that 
described the major causes of shortages for sterile injectables. 
 





State of the industry • The vast majority of the market is represented by only 7 
manufacturers. 
• Contract manufacturers act as both primary contract 
and secondary subcontract manufacturers. 
Lack of redundancy • Multiple products are made on existing manufacturing 
lines. 
• The 24-hour/7-day week production schedule provides 
no cushion of time. 
Complex manufacturing processes • Complex molecules do not allow for simple resolutions. 
• Problems typically affect multiple products at once. 
Investment economics uncertainties • For example, the ability to make a profit from producing 
propofol is questionable because a 20-mL vial sells for 
only $0.48.  At this time, there are 3 manufacturers of 
propofol. 
Quality and manufacturing issues • Sterility due to bacterial and fungal contamination 
• Particulates in glass, metal or fiber in vials 
• The potential for drugs to form crystals 
• Reaction between the drug and container or diluent 
• Potentially toxic impurities (e.g., heavy metals) 
• Degradants that result in less effective drug products 
• Breakdown of equipment 
• Natural disasters 
FDA’s role in drug shortages is to prioritize patient care as the top concern and ensure products 
are safe, effective and available.  Early notification of drug shortages is critical to FDA’s 
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involvement in developing prevention and mitigation strategies with manufacturers.  However, 
some shortages cannot be prevented due to an unforeseen breakdown in the manufacturing 
line or longstanding quality issues.  Some drug shortages can be addressed more rapidly than 
others, but FDA always considers the risks to patients at the outset. 
FDA’s prevention and mitigation strategies for drug shortages include prioritizing medically 
necessary products; weighing the risks and benefits of the drug; maintaining availability of the 
drug while minimizing the risk to patients; providing manufacturers with advice, assistance and 
expedited approaches to address problems; and offering flexible, creative and quick resolutions.  
FDA defines a “medically necessary drug” as a product used to treat or prevent a serious 
disease or medical condition for which no other alternative drug exists that is available in 
adequate supply and judged to be an adequate substitute by medical staff.  FDA solicits 
external expertise in the process of defining a medically necessary drug. 
FDA takes actions to promptly and efficiently respond to notifications of drug shortages by 
performing risk-based analyses and utilizing other tools.  FDA’s regulatory discretion allows the 
manufacture of medically necessary drugs to continue.  This tool is best suited for products that 
present a minor or low risk to patients, but additional safety controls might be required:  filters 
with the product, extra testing at the plant, third-party oversight of drug production, or special 
instructions for safe use.    
FDA requests other firms to increase production of the drug to address a public health need.  
FDA expedites inspections and reviews of proposals submitted by manufacturers, including 
longer expiration dates for drugs in the existing inventory, new manufacturing sites, new 
sources for raw materials, or changes in specifications.  FDA makes critical drugs temporarily 
available from unapproved sources in rare cases. 
FDA formed a Drug Shortage Task Force with staff from DSS and other offices.  FDA released 
its Strategic Plan on October 31, 2013 to strengthen its ability to respond to notices of a 
disruption in supply and improve its mitigation tools and communications.  FDA enhanced its 
“Drug Shortage Website” to more effectively communicate with stakeholders.  FDA is creating 
long-term prevention strategies to address the underlying causes of supply disruptions and 
prevent future drug shortages. 
FDA has identified three long-term prevention strategies to date:  (1) develop methods to 
incentivize and prioritize manufacturing quality; (2) establish a new Office of Pharmaceutical 
Quality that would use regulatory science to identify early warning signals of drug shortages; 
and (3) overcome existing limitations of data to increase knowledge and identify new 
approaches to address drug shortages. 
Overall, FDA will continue to strongly focus on drug shortages through a multidisciplinary 
approach involving clinicians, pharmacists, chemists, biotechnology firms, regulatory tools, 
manufacturers and public communication.  FDA also will strongly emphasize the need for 
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industry to commit to and institutionalize a new culture of quality manufacturing processes, 
methods and testing. 
The new culture of quality ideally will include redundancy of production through additional 
facilities and manufacturing lines, appropriate inspection and maintenance of facilities, prompt 
reporting and correction of even small production and quality problems, and ongoing dialogue 
with FDA on the best strategies to support quality manufacturing.  FDA will continue its close 
collaborations with manufacturers to prevent and mitigate shortages of critical drugs, but strong 
and multidisciplinary partnerships will be needed to resolve drug shortage problems. 







INH Tablets No supply issues; available from 2 manufacturers 
INH Injection No supply issues 
Rifampin Injection Available from a sole-source manufacturer; ability to meet demand 
Ethambutol Available from 2 manufacturers 
Amikacin Injection Available from 2 manufacturers 
Cycloserine Available 
Capreoymycin Available from a sole-source manufacturer 
 
ACET discussed the following topics with the FDA panel on TB drug shortages. 
 
• The ability of U.S. TB programs to obtain INH tablets from Canada. 
• The role of high user fees in hindering the ability to update older TB drug labels with 
newer clinical data and preventing overseas manufacturers from introducing their TB 
drugs to the U.S. market. 
• Ethical concerns and barriers to using quality, less expensive TB drugs sold through 
GDF in other countries, but not in the United States. 
• FDA’s regulatory restrictions on importing second-line drugs (SLDs) for TB patients, 
particularly if no other products are available in the United States to treat this patient 
population. 
• The definition of a “medically necessary drug” for an individual patient or public health. 
• Benefits to individual TB patients and the broader TB community due to FDA’s strong 
relationships with drug manufacturers. 
 
Update by the DTBE Drug Shortages Workgroup 
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Ann Cronin 
Associate Director for Policy and Issues Management, DTBE 
Centers for Disease Control and Prevention 
Ms. Cronin reported that the workgroup’s most recent discussions have focused on TB drug 
shortages and proactive approaches to prevent or mitigate future shortages.  She reviewed a 
table of TB drugs in the United States that are available or vulnerable to shortages.  The table 
illustrates the current status of 15 TB drugs: 
• Essential, first-line use (4 of 15 drugs) 
• Sole-source manufacturer in the United States (9 of 15 drugs) 
• Unavailable in the United States (1 drug only) 
• FDA approved and sold in the United States by specific manufacturers (14 of 15 drugs) 
• Non-FDA approved and sold through GDF by specific manufacturers (13 of 15 drugs) 
• Non-FDA approved and not sold by GDF (2 of 15 drugs) 
 
Ms. Cronin informed ACET of several key points in her review of the drug shortage table.  Oral 
and injectable Levofloxacin and oral Moxifloxacin were removed from the table because many 
manufacturers have FDA approval and sell these products in the United States.  Of all 15 drugs, 
Kanamycin is the only product that is unavailable in the United States. 
The FDA website maintains up-to-date company information on the manufacturer and the 
current status of TB drugs, including temporary disruption in supply and longer-term shortages.  
In this case, FDA can work with manufacturers to ship product (as it becomes available) to TB 
programs.  However, CDC has no role or oversight of local drug purchasing agreements with 
manufacturers. 
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
 
 
Minutes of the Meeting 
Advisory Council for the Elimination of Tuberculosis 
December 2-3, 2014  ♦  Page 27 
 
ANTI-TB DRUGS THAT ARE VULNERABLE TO SHORTAGES IN THE UNITED STATES 









Sold in U.S. by these 
manufacturers  
Not FDA Approved, 
Sold through GDF by these 
manufacturers  
Not FDA Approved 
Not Sold by GDF  








Capreomycin   X   Akorn Vianex    
Cycloserine   X   The Chao Center  Dong -- A ST Co; Macleods; 
Lupin  
  





Macleods; Cadila; Svizera  
  
Ethionamide       X   Norwich Pharmaceuticals 
for Wyeth 
Pharmaceuticals (Pfizer) 
Macleods; Lupin; Microlabs; 
Cipla  
  
Isoniazid (oral) X     Barr Laboratories for 
Teva; Epic Pharma for 
Sandoz; Mylan 





  X   Sandoz     
Kanamycin     X   Meiji; Panpharma   
Moxifloxacin 
(Injectable) 
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ANTI-TB DRUGS THAT ARE VULNERABLE TO SHORTAGES IN THE UNITED STATES 









Sold in U.S. by these 
manufacturers  
Not FDA Approved, 
Sold through GDF by these 
manufacturers  
Not FDA Approved 
Not Sold by GDF  
p-Aminosalicylic 
acid 
  X   Jacobus Pharm Olainfarm; Macleods   
Pyrazinamide X     ULTRAtab Laboratories 
for DAVA 
Pharmaceuticals; 
MIKART for VersaPharm  
Macleods; Cadilla; Labatec   
Rifabutin       Pfizer Italia for 
Pharmacia & Upjohn Co; 
Lupin Limited for Lupin 
Pharmaceuticals  
    
Rifampin X X    sanofi-aventis for sanofi-
aventis U.S. 
GDF only sells fixed-dose 
combinations: Lupin; 
Macleods; Strides; Svizera         
Patheon Italia for AKORN; 
Agila Specialties for 
Mylan; Agila Specialties 
for Pfizer;  
Rifapentine    X   sanofi-aventis for sanofi-
aventis U.S. 
Not sold by GDF   
Streptomycin   X   X-GEN Pharmaceuticals Reig Jofre Roerig (Pfizer) 
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Ms. Cronin asked ACET to consider long-term strategies that could be recommended to assure 
the availability of more TB drugs in the United States.  She pointed out that the workgroup has 
explored the pros and cons of several innovative approaches in this effort.  For example, an 
HHS facility could house a new mini-formulary for TB drugs, but DTBE does not have $20 
million to support this initiative.  BARDA could include TB in its list of necessary products for 
public health medical emergencies, but the start-up purchase of TB drugs from the BARDA 
stockpile and ongoing sustainability costs would require a tremendous amount of resources. 
Manufacturers that sell non-FDA-approved drugs through GDF could be encouraged to seek 
FDA approval to expand their market to the United States, particularly since these companies 
sell 13 of 15 first-line drugs (FLDs).  However, the level of interest in the manufacturing 
community for this small market is unknown.  Companies that do have FDA approval to sell 
product in the US may view encouragement of other companies to enter the US market as a 
disincentive to providing TB drugs. Incentives could be offered to manufacturers that produce 
old TB drugs to renew and maintain their interest in the market; however DTBE does not have 
resources or authority to provide these kinds of incentives. 
NTCA’s Perspective on the TB Drug Supply 
Donna Wegener 
Executive Director 
National Tuberculosis Controllers Association 
Ms. Wegener described NTCA’s perspective on the TB drug supply.  NTCA is aware that the TB 
drug supply in the United States prevents the spread of disease.  As a result, the new web-
based NTCA Reporting System was launched in November 2013 to collect and maintain various 
data elements on the TB drug supply.  The NTCA Reporting System provides real-time 
information and is a rich source of data to assess national TB drug shortages. 
NTCA acknowledges that the TB drug supply currently does not have significant or severe 
shortages as in the past, but weaknesses and vulnerabilities could lead to adverse changes.  
Most notably, only a few options exist for multi-drug TB regimens.  Drug shortages are 
continuing to worsen due to a procurement system that is decentralized across individual states.  
The number of manufacturers is limited.  The cost of TB drugs continues to increase.  A safety 
net has not been established for the TB drug supply.  Of 4 FLDs, 3 have a shortage or have 
experienced a large price increase.  Of 8 SLDs, 5 have a single manufacturer. 
The NTCA Reporting System captured several recent changes to the TB drug supply in 2014 at 
the state level.  A change in packaging for Cycloserine created confusion for suppliers.  The 
125% price increase for para-aminosalicylate sodium significantly impacted TB programs across 
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the country, particularly those with limited budgets.  Capreomycin had a limited, short-dated 
supply in California. 
Priftin was unavailable from a local supplier in Texas.  The “piecemeal” allocation of Tubersol in 
some states has affected TB contact investigations.  For example, TB controllers in North 
Dakota are only given 100 vials of Tubersol per month.  A large, low-incidence state 
encountered difficulties in acquiring Pyridoxine and was required to divert TB drugs from rural 
areas. 
NTCA currently is addressing key challenges in the TB drug supply.  The ability to maintain a 
sense of urgency is difficult because no TB drugs or diagnostics are in short supply or stock-out 
status at this time.  Problems with allocating TB drugs have not been resolved, particularly in the 
context of clearly defining roles of manufacturers, suppliers, distributors and state contractors.  
The cost of TB drugs is continuing to increase due to sole-source manufacturers, generic drugs 
and TB-specific drugs.  The cost of TB drugs is driving prescribing patterns.  For example, BDQ 
has a better safety and efficacy profile, but providers are continuing to prescribe Pyrazinamide 
more often due to its lower cost. 
Market forces are allowing large pharmaceutical companies to purchase smaller companies that 
produce TB drugs.  For example, Akorn received U.S. approval in August 2014 to purchase 
VersaPharm that manufactured a generic TB drug.  ACA has led to unintended consequences 
for some TB patients.  In California, for example, a previously healthy middle-aged immigrant 
with health insurance was diagnosed with MDR-TB. 
The patient purchased a health plan through the ACA Health Insurance Marketplace, but could 
not afford MDR-TB drugs that cost ~$5,000 each month.  The local health department in 
California attempted to apply wraparound services, but its resources are limited and cannot be 
sustained throughout the duration of the patient’s treatment.  To address TB-specific flaws in 
ACA, MDR-TB should be included in the Medicaid reimbursement exception for end-stage renal 
disease. 
Despite these challenges, NTCA is focusing its efforts on new partners and tools to improve the 
TB drug supply in the United States.  Ongoing communications, relationships and collaborations 
with industry have been strengthened.  The release of the President’s Executive Order, 
“Combating Antibiotic-Resistant Bacteria,” has given BARDA new authority to include TB and 
MDR-TB drugs in its list of necessary products for public health medical emergencies.  The U.S. 
Agency for International Development (USAID) has funded a new system to enhance access to 
pharmaceuticals and services.  USAID’s new electronic forecasting tool will be reviewed to 
determine potential opportunities to address issues in the domestic TB drug supply. 
Overall, risks to the U.S. TB drug supply are persistent despite progress that has been made 
over the past two years.  Sole-source manufacturers account for a large proportion of FLDs and 
SLDs.  Short- and long-term strategies need to be expedited to address vulnerabilities and 
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weaknesses in the current procurement system, such as interruptions in the TB drug/diagnostic 
supply, cost increases and limited access. 
ACET discussed the following topics with the DTBE Drug Shortages Workgroup and NTCA on 
the current status of the TB drug supply in the United States. 
• The feasibility of FDA pre-qualifying companies that could rapidly and temporarily import 
TB drugs when production problems arise with sole-source manufacturers. 
• The ability of NTCA to facilitate effective communications on the TB drug supply within 
and between TB programs. 
Status Report on the ACET Workgroups 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole announced that the terms of two former ACET members who chaired workgroups 
have expired.  In accordance with Federal Advisory Committee Act rules and regulations, 
current voting members of the parent company must chair workgroups.  Ms. Cole presented 
brief status reports and proposed next steps to ensure that the charges of the workgroups are 
fulfilled. 
ACET Essential Components Workgroup.  Ms. Cole reported that the workgroup was 
charged with reviewing and recommending updates to CDC’s 1995 document, “Essential 
Components of a TB Program.”  The workgroup presented several updates to ACET on its 
ongoing activities and progress in drafting a new document.  Ms. Cole expected the new 
Essential Components document to be presented during the next meeting for ACET’s review 
and discussion.  ACET’s formal vote on the draft document would fulfill the workgroup’s charge.  
ACET Corrections Workgroup.  Ms. Cole reported that ACET agreed by consensus to 
reestablish the workgroup during the June 2014 meeting with the following charge:  (1) evaluate 
activities DTBE has conducted to address ACET’s previous recommendations on TB in 
correctional settings; (2) review recent publications on the dramatic contribution of correctional 
settings to TB cases; and (3) serve as a liaison between ACET and the DTBE Corrections 
Workgroup. 
Ms. Cole noted that the workgroup has an existing charge, ongoing DTBE support to convene 
teleconference meetings, and DTBE staff to provide technical expertise.  She confirmed that the 
future direction of the workgroup would be revisited during the Business Session on the 
following day because no ACET voting members volunteered to serve as the new chair. 
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Update by the ACET Latent TB Infection Workgroup 
Robert Horsburgh, Jr., MD, MUS 
Professor of Epidemiology, Biostatistics and Medicine & Department of Epidemiology Chair 
Boston University School of Public Health 
ACET Member & Workgroup Chair 
Dr. Horsburgh covered the following topics in his update to ACET on the workgroup’s recent 
activities.  The workgroup was established during the June 2014 ACET meeting and soon 
learned that the NTCA TB Infection Survey Committee was addressing the same issues.  As a 
result, the workgroup began fulfilling its charge by engaging the NTCA Survey Committee as a 
key partner and reviewing the current LTBI literature. 
• Of all TB cases in the United States, 80% are attributed to reactivation of LTBI. 
• The current LTBI burden in the United States includes 11.2 million persons. 
• Only 50% of 200,000-300,000 persons who are treated for LTBI each year in the United 
States complete treatment. 
• TB regimens of shorter durations are expected to improve treatment completion rates. 
• The recently completed National Health and Nutrition Examination Survey (NHANES) is 
expected to provide an estimate of the proportion of LTBI patients who still need 
treatment. 
The workgroup described the rationale for developing an LTBI registry or reporting system.  An 
accurate estimate of the burden of LTBI would be provided.  Changes in LTBI would be 
monitored over time.  Populations at high risk for LTBI and in need of screening would be 
identified.  Source case investigations of LTBI would be facilitated, particularly for pediatric 
infections.  Awareness of and advocacy for the importance of LTBI would be increased. 
If the LTBI registry or reporting system also captured data on TB treatment initiation and 
completion, process indicators would be provided to assess progress toward TB elimination.  
Populations in need of assistance with TB treatment adherence would be identified.  Providers 
in need of TB education and outreach would be determined. 
The workgroup discussed the experiences of individual states in collecting and reporting LTBI 
data.  Kansas, Massachusetts, Mississippi, Missouri, New Hampshire and Rhode Island have 
mandatory LTBI reporting systems.  Massachusetts receives ~5,000 LTBI reports annually in its 
passive system and does not distinguish between the proportion of IGRAs and TSTs.  Missouri 
receives ~3,000 LTBI reports annually.  The system is extremely useful in conducting source 
case investigations and assuring that preventive therapy was offered.  Massachusetts and 
Missouri do not capture and monitor data on LTBI treatment completion rates. 
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New Hampshire receives ~1,200 LTBI reports annually and uses its system for targeted case 
management.  Maine and Tennessee have voluntary LTBI reporting systems.  Arizona, Georgia, 
New York City (NYC), Virginia and West Virginia have LTBI reporting systems for specific 
populations only, such as children. 
The workgroup analyzed the NYC LTBI reporting system as an initial case study.  The NYC 
system only captures pediatric LTBI cases at an incidence of 133-396 cases per year.  The 
NYC system could be used for locating source cases, but decreased funding has resulted in low 
reporting.  The NYC system has the capacity to retrospectively indicate potentially preventable 
cases that previously were identified as contacts.  The NYC system can serve as a source for 
baseline results that could be used to assess conversions in future contact investigations.  The 
NYC system also could serve as a source to evaluate underreporting of TB infection. 
The workgroup extensively discussed the NTCA TBI Survey that will be administered to TB 
controllers in the field in early 2015.  The workgroup noted that CDC is continuing to use “LTBI,” 
while NTCA has shifted to the terminology of “TB infection” (TBI).  In general, the survey will ask 
TB controllers to summarize any TB test result and describe both mandatory and voluntary TBI 
reporting practices.  In particular, the survey will ask TB controllers to respond to the following 
questions. 
• What data elements currently are reported and targeted to specific populations? 
• What level of patient and TBI information is reported to TB programs? 
• What is the extent to which TB programs are interested in receiving TBI test results and 
diagnoses? 
• What are the perceived benefits and challenges of a national reporting system for TBI 
test results and diagnoses? 
• What is the extent to which TB programs are interested in participating in activities to 
support reporting of TBI test results or diagnoses? 
The workgroup’s next steps will be to review NHANES data to identify the proportion of LTBI 
patients who previously were treated; analyze results of the NTCA TBI Survey of TB Controllers; 
estimate the workload for various LTBI reporting strategies; specify the costs and benefits of 
LTBI reporting; collaborate with the Tuberculosis Epidemiologic Studies Consortium to determine 
whether LTBI surveillance should be active or passive; and assess whether a new LTBI reporting 
system could be built on the existing contact investigation registry. 
Based on the discussion with ACET, Dr. Horsburgh confirmed that the workgroup would identify 
additional sources to collect and review LTBI data in an effort to estimate the true burden of LTBI 
in the United States. 
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Preparation for the ACET Business Session 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole summarized key points and outcomes from the day 1 presentations.  She asked ACET 
to consider topics that potentially could be developed as formal resolutions during the Business 




Topic to Consider 
 
DTBE Director’s Report • Strategies to leverage and apply components of CDC’s 
ebola response to TB 
• The 5 strategies for TB elimination in the United States 
NCHHSTP’s Health Equity Activities • Approaches to include health equity concepts in TB 
elimination efforts 
Status of TB Elimination in the Field • ACET’s formal support of the Stop TB USA 2010 TB 
Elimination Plan 
TB Drug Shortages • Long-term strategies to assure the availability of more 
TB drugs in the United States 
LTBI Workgroup • New and more effective messaging to shift to TB 
elimination (e.g., replace “LTBI” with “TBI”) 
 
With no further discussion or business brought before ACET, Ms. Cole recessed the meeting at 
4:34 p.m. on December 2, 2014. 
Opening Session: December 3, 2014 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer 
Dr. Dean conducted a roll call to determine the ACET voting members, ex-officio members and 
liaison representatives who were attending the meeting either in person or remotely.  She 
announced that ACET meetings are open to the public and all comments made during the 
proceedings are a matter of public record. 
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Dr. Dean reminded the ACET voting members of their responsibility to disclose any potential 
individual and/or institutional conflicts of interest for the public record and recuse themselves 
from voting or participating in these matters.  None of the voting members publicly disclosed any 
individual or institutional conflicts of interest for the record that were new or different than those 
declared on day 1 of the meeting. 
Dr. Dean announced that the voting members and ex-officio members in attendance constituted 
a quorum for ACET to conduct its business on December 3, 2014.  She reconvened the 
proceedings at 8:40 a.m. and welcomed the participants to day 2 of the ACET meeting. 
ACET Business Session 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole opened the business session and called for ACET’s review, discussion and/or formal 
action on the following topics. 
Topic 1: ACET’s Process to Respond to Requests for Advice 
Ms. Cole was pleased that ACET initiated a process during the June 2014 meeting to monitor 
the status of its recommendations to CDC in a more formal, systematic and ongoing manner.  
However, she emphasized that a similar process is needed to ensure ACET responds to 
specific advice requested by CDC.  She moderated a discussion on the current status of 
ACET’s responses to CDC’s previous requests for advice. 
 






MARCH 4, 2014 MEETING 
ACET’s guidance to HHS to prevent TB 
drug shortages in the future. 
NTCA ACET took a formal vote to establish a 
new TB Drug Shortages Workgroup.  The 
motion unanimously passed by 10 
ACET voting members.  Ms. Jennifer 
Cochran and Dr. Susan Dorman will serve 
as co-chairs.  The workgroup will initiate 
its activities based on the following draft 
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• Concrete recommendations to the 
HHS Secretary will be drafted by the 
next meeting for ACET’s review, 
discussion and formal action.  The 
workgroup will extensively discuss the 
innovative strategies Ms. Ann Cronin 
has explored to address TB drug 
shortages in the United States. 
• The HHS Secretary will be informed 
that collaborations over the past two 
years among CDC, FDA, USAID and 
other federal partners to address TB 
drug shortages have not generated 
any resolutions to the problem due to 
existing regulatory and legal barriers.  
The public health impact of TB drug 
shortages will be emphasized as well. 
• The HHS Secretary will be provided 
with broader recommendations on drug 
shortages for non-infectious diseases, 
such as cancer drug shortages, to 
increase public attention. 
ACET’s recommendations on CDC’s 
global health activities: 
• CDC’s global TB measures and targets 
• Global TB Steering Committee 
• Global TB Strategic Framework and the 
Global TB Strategic Plan 
• TB Building and Strengthening 






ACET agreed to schedule Dr. Susan 
Maloney, the CDC Global TB Coordinator, 
on the next agenda to provide an update 
on CDC’s Global TB Strategic Plan.  
ACET will formulate recommendations at 
that time. 
JUNE 9-10, 2014 MEETING 
ACET’s collaboration with the DTBE 
Corrections Workgroup and other 
correctional partners to create a national 
strategic action plan for TB prevention 
and control in correctional facilities. 
DTBE • The ACET Corrections Workgroup will 
suspend all activities until its charge is 
redefined and a current voting member 
volunteers to serve as the new chair. 
• ACET agreed to schedule a status 
report on the workgroup’s most recent 
activities on the next agenda. 
• ACET agreed to schedule the DTBE 
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Corrections Workgroup on the next 
agenda to present an update on its 
“partially implemented” and “ongoing” 
activities in response to ACET’s 
previous resolutions. 
ACET’s input on the USPSTF Draft 
Research Plan on LTBI. 
DTBE ACET submitted its guidance to USPSTF.  
With the exception of recommending LTBI 
treatment as primary prevention, all of 
ACET’s other suggestions were accepted 
by USPSTF and are included in the final 
research plan.  ACET will continue to 
monitor this issue over the next year. 
DECEMBER 2-3, 2014 MEETING 
ACET’s support of the 2010 TB 
Elimination Plan: 
(1) Will ACET resolve to reaffirm and 




(2) Will ACET strongly encourage HHS 
and CDC to implement the 2010 TB 





(3) Will ACET ask the Federal TB Task 






(1) ACET took a formal vote and resolved 
to reaffirm and endorse the 2010 TB 
Elimination Plan.  The motion passed by 
a majority vote of 9 in favor and 1 
abstention (Dorman). 
(2) ACET took a formal vote to 
recommend to the HHS Secretary and 
CDC Director to implement the 2010 TB 
Elimination Plan.  The motion passed by 
a majority vote of 7 in favor, 1 opposed 
(Sunstrum), and 2 abstentions 
(Cochran and Dorman). 
(3) ACET agreed that DTBE, as the lead 
of the Federal TB Task Force, will provide 
periodic updates on the status of 
implementing the 2010 TB Elimination 
Plan.  CDC’s federal partners and non-
governmental organizations will be invited 
to the next meeting to present updates to 
ACET:  NIH, USAID, Gates Foundation 
and the Treatment Action Group (TAG). 
(1) ACET’s input on essential issues to 
consider for TB elimination in developing 
training and educational materials to 
increase knowledge of health equity 
concepts. 





ACET agreed to invite the new DTBE 
Health Equity Coordinator to the next 
meeting to provide a more focused 
overview of health equity issues in the 
context of TB elimination.  ACET will 
formulate recommendations at that time. 
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health equity for TB elimination at state 
and local levels and specific strategies to 
operationalize to achieve health equity for 
TB elimination. 
Topic 2: Draft ACET Meeting Minutes 
Ms. Cole entertained a motion for ACET to approve the previous meeting minutes.  A motion 
was properly placed on the floor by Ms. Jennifer Cochran and seconded by Dr. Ana Alvarez for 
ACET to approve the previous meeting minutes. 
The motion for ACET to adopt the Draft June 9-10, 2014 Meeting Minutes was tied with 5 
members in favor and 5 abstentions by the new members:  Armitige, Houpt, Lauzardo, 
Sunstrum and Warshauer. 
Topic 3: ACET Report to the HHS Secretary (2011-2013) 
Ms. Cole informed the new members that ACET discussed its Report to the HHS Secretary 
(2011-2013) during the previous meeting.  The HHS Secretary sent a letter to CDC 
acknowledging receipt of the report.  Ms. Cole asked ACET to propose next steps in this regard. 
Dr. Dean emphasized that progress on implementing the recommendations in ACET’s report 
has been delayed due to changes in leadership within the Office of the HHS Secretary and the 
ebola outbreak.  She advised the Chair to send a follow-up letter to the new HHS Secretary to 
request a meeting to discuss ACET’s report.  The report should be attached to the letter. 
ACET proposed several topics that should be prioritized in Ms. Cole’s meeting with the HHS 
Secretary. 
• TB drug shortages 
• TB in correctional settings 
• Scale-up of LTBI treatment 
• TB funding in the context of the role of ACA in TB elimination 
• TB disparities and health equity issues 
• TB in foreign-born populations 
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• The lack of progress on implementing recommendations in the 2000 IOM TB elimination 
report 
• The importance of maintaining a strong public health infrastructure in light of the ebola 
outbreak 
• Alignment of TB issues with the overarching vision, strategic direction and priorities of 
the HHS Secretary 
Dr. Dean reminded ACET of its previous suggestion for the Chair to attend a briefing with Dr. 
Frieden or his designee after each meeting to summarize key outcomes and elevate the 
importance of TB at the level of the CDC Director.  To advance this suggestion, Dr. Dean 
confirmed that she would schedule a briefing with Ms. Cole and Dr. Frieden after the March 
2015 ACET meeting.  If Dr. Frieden is unavailable, Ms. Cole will meet with Dr. Ileana Arias, 
Principal Deputy Director of CDC. 
Topic 4: TB Research Agenda 
Dr. LoBue reported that the DTBE Research Workgroup has completed three key tasks since 
the previous ACET meeting:  developed an inventory of ongoing and emerging research 
projects, formed an internal research oversight board, and identified existing gaps in TB 
research.  The oversight board currently is fulfilling its charge of reviewing DTBE’s entire TB 
research portfolio and ranking individual projects by their level of priority for inclusion in the 
research agenda. 
Dr. LoBue noted that additional tasks need to be completed before the TB research agenda can 
be finalized, such as hiring a new DTBE Associate Director for Science and conducting an 
external peer review of the draft research agenda with at least one ACET member and other 
external experts.  Dr. LoBue confirmed that he would notify Dr. Dean when the draft TB 
research agenda could be presented to ACET for review and comment. 
Topic 5: New TB Nurse Consultant 
Ms. Cole informed the new members that ACET presented the concept of a resolution during 
the previous meeting for CDC to hire a new TB Nurse Consultant (TBNC).  The important role of 
a TBNC in DTBE was emphasized, but ACET acknowledged that advising CDC on personnel 
decisions was outside the scope of its advisory role. 
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Topic 6: ACET’s New Organizational Structure 
Ms. Cole moderated ACET’s discussion on its new organizational structure in terms of more 
systematically tracking its formal guidance and action items to CDC, responding to CDC’s 
requests for advice in a timelier manner, and convening in-person meetings versus webinars. 
• The Agenda Setting Workgroup is to be commended.  The current agenda was 
extremely responsive to ACET’s requests for future agenda items, particularly the series 
of presentations on the TB drug supply in the United States. 
• The new part of the Business Session for ACET to strategically respond to CDC’s 
requests for advice was tremendously helpful.  This new process will strengthen ACET’s 
advisory role in providing CDC with the most helpful and useful guidance to advance 
toward TB elimination. 
• Efforts to schedule regular briefings with the CDC Director or his designee and meet with 
the HHS Secretary will be valuable in promoting the “Think TB” concept at high levels of 
government. 
• Ms. Cole’s succinct summary of key points and outcomes from the day 1 presentations 
are enormously helpful for the ACET members to prepare for the Business Session. 
• The change in the schedule that allowed the five new members to attend their first 
meeting in person rather than by webinar will increase ACET’s overall effectiveness in 
the future. 
• CDC should ensure that new members are provided with important materials in advance 
of attending their first meeting.  For the current meeting, for example, the new members 
should have been given the June 9-10, 2014 minutes, ACET Report to the HHS 
Secretary (2011-2013), the 2010 TB Elimination Plan, and the USPSTF Final Research 
Plan on LTBI. 
• ACET should continue its efforts to convene two in-person meetings and one webinar 
per fiscal year.  Webinars should be held in conjunction with other events that will be 
well attended by ACET members, such as the annual NTCA meeting.  An additional 
webinar should be incorporated into the meeting schedule in order for ACET to maintain 
momentum on TB elimination, particularly the six months between the June and 
December meetings. 
• CDC should hold ACET meetings by video conferencing because this technology is 
vastly superior to webinars.  Moreover, ex-officio members count toward a quorum and 
could meet at an HHS facility in the DC metropolitan area to attend ACET meetings by 
video conferencing. 
Drs. Dean and LoBue responded to some of ACET’s suggestions.  DTBE has no authority to 
change federal policy of convening only one in-person meeting per fiscal year.  All of CDC’s 
Federal Advisory Committees likely would make the same request if an exception was made for 
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ACET.  CDC will switch to a new technology platform in 2015, but the capability of utilizing video 
conferencing rather than webinars is unknown at this time. 
Topic 7: Potential ACET/BARDA Collaboration 
Ms. Donna Wegener, Executive Director of NTCA, reported that efforts have been underway for 
the past year to build collaboration between ACET and BARDA.  NTCA, TAG, the American 
Thoracic Society, and the Association of State and Territorial Health Officials met with Dr. Robin 
Robinson, Director of BARDA, in 2013 to raise the visibility of TB preparedness and drug 
shortage issues.  Dr. Robinson expressed an interest in increasing the focus on TB, but was 
uncertain whether TB was in BARDA’s current purview. 
Dr. Robinson noted the restrictions in initiating new activities because President’s Executive 
Orders and the HHS Secretary define and establish BARDA’s focus and agenda.  DTBE and 
the Infectious Diseases Society of America joined the other professional societies in attending a 
follow-up meeting with BARDA after a new Executive Order, “Combating Antibiotic-Resistant 
Bacteria,” was released in September 2014.  The purpose of the follow-up meeting was to 
emphasize the critical need to incorporate MDR-/XDR-TB into the BARDA agenda. 
Dr. Robinson clarified that a directive from the HHS Assistant Secretary for Health (ASH) would 
allow BARDA to refocus or reframe a portion of its agenda to include “reemerging” public health 
issues.  TB would be included on this list.  ACET was mentioned as a potential mechanism to 
make the formal request to ASH to allow BARDA to expand its focus. 
Chair’s call for a vote Motion properly made by Dr. James Sunstrum for ACET to request 
that the HHS Assistant Secretary for Health direct BARDA to 
address MDR-/XDR-TB treatment issues. 
Motion seconded by Dr. Robert Horsburgh, Jr. 
Outcome of vote Motion unanimously passed by 10 ACET voting members 
Next steps Ms. Cole will convey the request in the same letter that will be sent 





Topic 8: Agenda Items 
Ms. Cole led ACET in a review of the status of 7 new agenda items that were proposed during 
the previous meeting.  Topics 2, 3 and 4 were presented during the current meeting. 
 
 
Minutes of the Meeting 
Advisory Council for the Elimination of Tuberculosis 
December 2-3, 2014  ♦  Page 42 
 
• Topic 1, development of a new Global TB Drug Resistance Database, would be placed 
on a future agenda. 
• Topic 5, HRSA’s role in TB elimination, would be placed on a future agenda, but would 
be expanded beyond HRSA. 
• Topic 6, the TB cascade of care, was not revisited. 
• Topic 7, national LTBI reporting, would be tabled until the LTBI Workgroup presented its 
draft recommendations to ACET. 
For the current meeting, Ms. Cole noted that ACET proposed several new agenda items during 
its responses to CDC’s previous requests for advice.  She opened the floor for ACET to request 
additional items to place on future agendas. 





(DTBE) Dr. Philip LoBue 
1. Status report on DTBE’s meeting with TB controllers on 
potential strategies to scale-up TB treatment, particularly for 
high-risk populations 
(DTBE) Dr. Philip LoBue 2. Update on TB drugs in the pipeline 
NTCA 3. The impact of funding cuts on TB programs in the field 
Select TB Programs & National 
Organizations 
4. Overview of best practices to engage communities in 
addressing TB in foreign-born populations 
ACET Membership 
5. Discussion on strategies to publicize the importance of the 
nursing role in TB control and emphasize the need for a 
national nursing presence 
Topic 9: Action Items 
Ms. Cole noted that ACET addressed and obtained status reports on action items 1, 3, 6 and 7 
from the previous meeting.  Action items 2, 4 and 5 were the responsibility of former or absent 
ACET members.  She planned to follow-up with these individuals to determine whether the 
action items had been completed. 
For the current meeting, Ms. Cole noted that ACET proposed several new action items during 
its responses to CDC’s previous requests for advice.  She opened the floor for ACET to request 
additional tasks. 
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ACTION ITEMS 
Responsibility Action Step 
DTBE (Ms. Suzanne Marks) 1. Provide the LTBI Workgroup with LTBI test results that DTBE collected from private-sector databases 
ACET Committee Management 
Specialist 
2. Provide the five new members with the ACET Report to the 
HHS Secretary (2011-2013) [completed during the meeting] 
and the USPSTF Final Research Plan on LTBI 
ACET Chair 
3. Reestablish the Agenda Setting Workgroup with new 
members 
• Ms. Barbara Cole, chair 
• Dr. Lisa Armitige 
• Dr. Robert Horsburgh, Jr. 
• Dr. Michael Lauzardo 
[Completed during the meeting] 
Agenda Setting Workgroup 
4. Propose strategies to maximize the effectiveness and 
productivity of ACET meetings that are held via webinar 
during the next teleconference in early January 2015 
ACET Committee Management 
Specialist 
5. Circulate an e-mail message to inform ACET when the 
public comment period is opened on the USPSTF Final 
Research Plan on LTBI 
Public Comment Session 
Donna Wegener 
Executive Director 
National Tuberculosis Controllers Association 
Ms. Wegener made the following comments for ACET’s consideration.  Nurses are the driving 
force of TB control programs.  A new TB Nurse Consultant (TBNC) position in DTBE would be 
extremely important to TB programs in the field in terms of having a nursing perspective and a 
voice at federal, state and local levels.  Ideally, the TBNC would be housed in the DTBE Field 
Services and Evaluation Branch.  NTCA is willing to support a national nurse presence if a 
professional society is a more appropriate or feasible option for the TBNC position than a 
federal agency. 
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The next three ACET meetings are tentatively scheduled for March 3, 2015 (a webinar), June 2, 
2015 (a webinar), and December 1-2, 2015 (an in-person meeting in Atlanta or a webinar).  
Based on ACET’s comments, CDC confirmed that the December 2015 meeting would be 
rescheduled due to a conflict with the International Union Against Tuberculosis and Lung 
Disease conference. 
With no further discussion or business brought before ACET, Ms. Cole adjourned the meeting at 
12:13 p.m. on December 3, 2014. 
Dr. Dean will publish a Federal Register notice to inform the public that ACET concluded its 
business before 2:30 p.m. as noted on the published agenda.  The notice also will confirm that 
the ACET Chair opened the public comment session at 12:10 p.m. rather than at 2:20 p.m. as 
noted on the published agenda. 
 
       I hereby certify that to the best of my 
       knowledge, the foregoing Minutes of the 
       proceedings are accurate and complete. 
___________________    ___________________________________ 
Date       Barbara Cole, RN, MSN, PHN 
       Chair, Advisory Council for the 
       Elimination of Tuberculosis 
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ACET Members Present 
Ms. Barbara Cole, Chair 
Dr. Ana Alvarez 
Dr. Lisa Armitige 
Ms. Jennifer Cochran 
Dr. Susan Dorman 
Dr. Robert Horsburgh, Jr. 
Dr. Eric Houpt 
Dr. Michael Lauzardo 
Dr. James Sunstrum 
Dr. David Warshauer 
ACET Ex-Officio Members Present 
Dr. Naomi Aronson 
Department of Defense 
Dr. William Baine 
Agency for Healthcare Research and 
Quality 
Dr. Michael Bartholomew 
(Alternate for Dr. Susan Karol) 
Indian Health Services 
Dr. Amy Bloom 
U.S. Agency for International Development 
CDR Edward Chin 
United States Marshals Service 
Ms. Marla Clifton 
(Alternate for Dr. Gary Roselle) 
U.S. Department of Veteran Affairs 
Dr. Diana Elson 
U.S. Immigration and Customs Enforcement 
Ms. Caroline Freeman 
U.S. Department of Labor, 
Occupational Safety and Health 
Administration 
Dr. Nadine Gracia 
Office of Minority Health 
U.S. Department of Health and Human 
Services 
Dr. Mamodikoe Makhene 
National Institute of Allergy and Infectious 
Diseases, National Institutes of Health 
Ms. Marlene Matosky 
(Alternate for Dr. Rupali Doshi) 
HIV/AIDS Bureau, Health Resources and 
Services Administration 
Dr. Chana Rabiner 
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Dr. Susan Robilotto 
(Alternate for Dr. Rupali Doshi) 
HIV/AIDS Bureau, Health Resources and 
Services Administration 
ACET Ex-Officio Members Absent 
Ms. Sarah Bur 
Federal Bureau of Prisons 
Dr. Rupali Doshi 
HIV/AIDS Bureau, Health Resources and 
Services Administration 
Dr. Susan Karol 
Indian Health Service 
Mr. Stephen Martin 
National Institute for Occupational Safety 
and Health 
Dr. Sheldon Morris 
U.S. Food and Drug Administration 
Dr. Gudelia Rangel 
Mexico Section, U.S.-Mexico Border Health 
Commission 
Dr. Gary Roselle 
U.S. Department of Veteran Affairs 
Dr. Bruce San Filippo 
U.S. Section, U.S. Mexico Border Health 
Commission 
ACET Liaison Representatives 
Present 
Dr. Shama Ahuja 
Council of State and Territorial 
Epidemiologists 
Dr. Robert Benjamin 
National Association of County and City 
Health Officials 
Dr. John Bernardo 
National Tuberculosis Controllers 
Association 
RESULTS 
Mr. Kenyon Farrow 
(Alternate for Ms. Colleen Daniels) 
Treatment Action Group 
Dr. Amee Patrawalla 
American College of Chest Physicians 
Dr. Susan Ray 
Infectious Disease Society of America 
Dr. Randall Reves 
International Union Against TB and Lung 
Disease 
Ms. Tara Wildes 
National Commission on Correctional 
Health 
ACET Liaison Representatives 
Absent 
Ms. Colleen Daniels 
Treatment Action Group 
Dr. Fran du Melle 
American Thoracic Society 
Dr. Mayleen Ekiek 
Pacific Island Health Officers Association 
Mr. Eddie Hedrick 
Association for Professionals in Infection 
Control and Epidemiology 
Dr. Ilse Levin 
American Medical Association 
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Dr. Saul Levin 
Association of State and Territorial Health 
Officials 
Mr. John Lozier 
National Coalition for the Homeless 
Ms. Eileen Napolitano 
Stop TB USA 
Dr. Howard Njoo 
Public Health Agency of Canada 
Dr. Jennifer Rakeman 
Association of Public Health Laboratories 
Dr. Michael Tapper 
Society for Healthcare Epidemiology of 
America 
Dr. Lornel Tompkins 
National Medical Association 
ACET Designated Federal Officer 
Dr. Hazel Dean 
NCHHSTP Deputy Director 
CDC Representatives 
Ms. Leeanna Allen 
Mr. Gustavo Aquino 
Mr. Glen Christie 
Ms. Ann Cronin 
Mr. Justin Davis 
Dr. Wayne Duffus 
Ms. Teresa Durden 
Ms. Maria Fraire-Sessions 
Dr. Christine Ho 
Dr. John Jereb 
Dr. Awal Khan 
Ms. Kathryn Koski 
Ms. Ann Lanner 
Dr. Philip LoBue 
Ms. Suzanne Marks 
Ms. Margie Scott-Cseh 
Dr. Neha Shah 
Dr. Andrew Vernon 
Dr. Richard Wolitski 
Members of the Public 
Mr. Sahil Angelo 
Center for Strategic and International 
Studies 
Dr. Phillip Nieburg 
Center for Strategic and International 
Studies 
Mr. David Roeder 
U.S. Food and Drug Administration 
Dr. Jouhayna Saliba 
U.S. Food and Drug Administration 
Ms. Donna Wegener 
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Glossary of Acronyms 
3HP Three-month, once-weekly Isoniazid/Rifapentine 
ACA Affordable Care Act 
ACET Advisory Council for the Elimination of Tuberculosis 
ANDA Abbreviated New Drug Application 
ASH Assistant Secretary for Health 
BARDA Biomedical Advanced Research and Development Authority 
BCG Bacillus Calmette-Guérin 
BDQ Bedaquiline 
BLAs Biologics License Applications 
CBOs Community-Based Organizations 
CDC Centers for Disease Control and Prevention 
DFO Designated Federal Officer 
DHAP Division of HIV/AIDS Prevention 
DOT Directly Observed Therapy 
DSS Drug Shortage Staff 
DTBE Division of Tuberculosis Elimination 
FBPs Foreign-Born Persons 
FDA U.S. Food and Drug Administration 
FDASIA FDA  Safety and Innovation Act 
FLDs First-Line Drugs 
GDF Global Drug Facility 
HHS U.S. Department of Health and Human Services 
HRSA Health Resources and Services Administration 
IGRAs Interferon Gamma Release Assays 
INH Isoniazid 
IOM Institute of Medicine 
LTBI Latent TB Infection 
MDR-TB Multidrug-Resistant TB 
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
NDA New Drug Application 
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NHANES National Health and Nutrition Examination Survey 
NIH National Institutes of Health 
NTCA National Tuberculosis Controllers Association 
NYC New York City 
OD Office of Director 
OHE Office of Health Equity 
PEPFAR President’s Emergency Plan for AIDS Relief 
PRVs Priority Review Vouchers 
QIDP Qualified Infectious Disease Product 
RTMCCs Regional Training and Medical Consultation Centers 
SDH Social Determinants of Health 
SLDs Second-Line Drugs 
TAG Treatment Action Group 
TB Tuberculosis 
TBI TB Infection 
TBNC TB Nurse Consultant 
TST Tuberculin Skin Test 
USAID U.S. Agency for International Development 
USPSTF U.S. Preventive Services Task Force 
WHO World Health Organization 
XDR-TB Extensively Drug-Resistant TB 
 
